230 related articles for article (PubMed ID: 29416297)
1. The adipokines in the pathogenesis and treatment of nonalcoholic fatty liver disease.
Boutari C; Tziomalos K; Athyros VG
Hippokratia; 2016; 20(4):259-263. PubMed ID: 29416297
[TBL] [Abstract][Full Text] [Related]
2. Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease.
Boutari C; Perakakis N; Mantzoros CS
Endocrinol Metab (Seoul); 2018 Mar; 33(1):33-43. PubMed ID: 29589386
[TBL] [Abstract][Full Text] [Related]
3. Adipokines in nonalcoholic fatty liver disease.
Polyzos SA; Kountouras J; Mantzoros CS
Metabolism; 2016 Aug; 65(8):1062-79. PubMed ID: 26725002
[TBL] [Abstract][Full Text] [Related]
4. [The role of adipokines and insulin resistance in the pathogenesis of nonalcoholic fatty liver disease].
Orlik B; Handzlik G; Olszanecka-Glinianowicz M
Postepy Hig Med Dosw (Online); 2010 May; 64():212-9. PubMed ID: 20498498
[TBL] [Abstract][Full Text] [Related]
5. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.
Stojsavljević S; Gomerčić Palčić M; Virović Jukić L; Smirčić Duvnjak L; Duvnjak M
World J Gastroenterol; 2014 Dec; 20(48):18070-91. PubMed ID: 25561778
[TBL] [Abstract][Full Text] [Related]
6. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis.
Hohenester S; Christiansen S; Nagel J; Wimmer R; Artmann R; Denk G; Bischoff M; Bischoff G; Rust C
Am J Physiol Gastrointest Liver Physiol; 2018 Sep; 315(3):G329-G338. PubMed ID: 29878845
[TBL] [Abstract][Full Text] [Related]
7. Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?
Francisco V; Sanz MJ; Real JT; Marques P; Capuozzo M; Ait Eldjoudi D; Gualillo O
Biology (Basel); 2022 Aug; 11(8):. PubMed ID: 36009862
[TBL] [Abstract][Full Text] [Related]
8. Serum adipokine levels in overweight patients and their relationship with non-alcoholic fatty liver disease.
Abenavoli L; Luigiano C; Guzzi PH; Milic N; Morace C; Stelitano L; Consolo P; Miraglia S; Fagoonee S; Virgilio C; Luzza F; De Lorenzo A; Pellicano R
Panminerva Med; 2014 Jun; 56(2):189-93. PubMed ID: 24994581
[TBL] [Abstract][Full Text] [Related]
9. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease.
Polyzos SA; Kountouras J; Zavos C; Tsiaousi E
Diabetes Obes Metab; 2010 May; 12(5):365-83. PubMed ID: 20415685
[TBL] [Abstract][Full Text] [Related]
10. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy.
Tsochatzis EA; Papatheodoridis GV; Archimandritis AJ
Mediators Inflamm; 2009; 2009():831670. PubMed ID: 19753129
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting the serum levels of adipokines in Korean male patients with nonalcoholic fatty liver disease.
Cho YK; Lee WY; Oh SY; Park JH; Kim HJ; Park DI; Sohn CI; Jeon WK; Kim BI; Kim SW; Oh KW; Yun EJ; Oh ES
Hepatogastroenterology; 2007; 54(77):1512-6. PubMed ID: 17708287
[TBL] [Abstract][Full Text] [Related]
12. Serum concentration of adiponectin, leptin and resistin in obese children with non-alcoholic fatty liver disease.
Lebensztejn DM; Wojtkowska M; Skiba E; Werpachowska I; Tobolczyk J; Kaczmarski M
Adv Med Sci; 2009; 54(2):177-82. PubMed ID: 20022856
[TBL] [Abstract][Full Text] [Related]
13. Adipocytokines in nonalcoholic fatty liver disease: key players regulating steatosis, inflammation and fibrosis.
Tilg H
Curr Pharm Des; 2010 Jun; 16(17):1893-5. PubMed ID: 20370678
[TBL] [Abstract][Full Text] [Related]
14. Serum adiponectin, leptin, resistin and RBP4 levels in obese and metabolic syndrome children with nonalcoholic fatty liver disease.
Boyraz M; Cekmez F; Karaoglu A; Cinaz P; Durak M; Bideci A
Biomark Med; 2013 Oct; 7(5):737-45. PubMed ID: 24044566
[TBL] [Abstract][Full Text] [Related]
15. Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease.
Nobili V; Carpino G; Alisi A; Franchitto A; Alpini G; De Vito R; Onori P; Alvaro D; Gaudio E
Hepatology; 2012 Dec; 56(6):2142-53. PubMed ID: 22467277
[TBL] [Abstract][Full Text] [Related]
16. Regular exercise coupled to diet regimen accelerates reduction of hepatic steatosis and associated pathological conditions in nonalcoholic fatty liver disease.
Oh S; Tanaka K; Tsujimoto T; So R; Shida T; Shoda J
Metab Syndr Relat Disord; 2014 Jun; 12(5):290-8. PubMed ID: 24689911
[TBL] [Abstract][Full Text] [Related]
17. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement.
Lutchman G; Promrat K; Kleiner DE; Heller T; Ghany MG; Yanovski JA; Liang TJ; Hoofnagle JH
Clin Gastroenterol Hepatol; 2006 Aug; 4(8):1048-52. PubMed ID: 16814613
[TBL] [Abstract][Full Text] [Related]
18. [Adipocytokines and nonalcoholic steatohepatitis].
Lăcătuşu C; Mihai B; Mihai C; Cijevschi-Prelipcean C; Graur M
Rev Med Chir Soc Med Nat Iasi; 2009; 113(2):345-52. PubMed ID: 21495339
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines.
Polyzos SA; Kountouras J; Zavos C
Curr Mol Med; 2009 Apr; 9(3):299-314. PubMed ID: 19355912
[TBL] [Abstract][Full Text] [Related]
20. Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis.
Ismaiel A; Leucuta DC; Popa SL; Dumitrascu DL
J Clin Med; 2021 Jul; 10(14):. PubMed ID: 34300193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
